Why Staging Matters
After a prostate cancer diagnosis, one of the first priorities is understanding how far the disease has spread. This process is called staging. Staging determines whether the cancer is confined to the prostate, has reached nearby lymph nodes, or has spread to distant sites such as bones or other organs. The stage directly influences treatment decisions.
A patient with cancer confined to the prostate may be a candidate for surgery or focused radiation. A patient with widespread disease may need systemic treatment such as hormone therapy, chemotherapy, or radioligand therapy. Accurate staging ensures patients receive the treatment that matches their actual disease burden.
How Imaging Contributes to Staging
Staging combines information from several sources: PSA blood levels, biopsy results (Gleason score and grade group), physical examination, and imaging. Imaging provides the visual evidence of where the cancer is located in the body.
Traditional imaging for prostate cancer staging included CT scans and bone scans. CT scans detect enlarged lymph nodes, while bone scans look for areas of increased bone activity that may indicate metastases. However, both have limitations. CT cannot detect cancer in normal-sized lymph nodes, and bone scans can produce false positives from arthritis or old injuries.
How PSMA PET CT Changed Prostate Cancer Staging
PSMA PET CT scans target the PSMA protein on prostate cancer cells, detecting disease at a molecular level. This allows the scan to find cancer deposits that are too small to appear on conventional CT or bone scans.
Studies have demonstrated that PSMA PET CT identifies additional disease sites in a meaningful proportion of patients compared to conventional imaging. This changes the stage assessment in some cases, which can alter the recommended treatment. For example, a patient initially thought to have localised disease based on CT and bone scan may be found to have lymph node involvement on PSMA PET CT, leading to a different treatment approach.
Staging and Treatment Decisions
Localised disease: If the cancer appears confined to the prostate, options typically include surgery (radical prostatectomy), radiation therapy, or in some cases, active surveillance. The choice depends on the grade, PSA level, and patient preferences.
Regional spread: If the cancer has reached nearby lymph nodes, treatment may involve a combination of surgery and radiation, often with hormone therapy. The extent of lymph node involvement guides how aggressive the treatment needs to be.
Distant metastases: If the cancer has spread to bones or other organs, systemic treatments become the focus. These include hormone therapy, chemotherapy, and in appropriate cases, Lu-177 PSMA therapy.
The staging information from PSMA PET CT helps doctors match the intensity of treatment to the actual extent of disease, avoiding both undertreatment and overtreatment.
Discuss Staging with Your Doctor
If you have been recently diagnosed with prostate cancer, ask your doctor about the role of PSMA PET CT in your staging workup. The scan may provide additional information beyond conventional imaging that could influence your treatment plan. Your oncologist and nuclear medicine physician can advise whether it is appropriate for your specific case.